Digest Network Come funziona
Network
/
Società
OB
Non verificato

OBI Pharma Inc.

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione Aziendale

9 comunicati stampa

Guarda tutti i comunicati
06/06/2025
Farmaceutica
Management/Organizzazione Aziendale
Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
06/06/2025
Farmaceutica
Management/Organizzazione Aziendale
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
01/05/2025
Farmaceutica
OBI Pharma reçoit l’approbation de la FDA à la suite de sa demande d’étude clinique de la Phase I/II pour OBI-902, un CAM ciblant Trop-2
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/04/2025
Farmaceutica
OBI Pharma annonce l’exposition d’affiches au congrès annuel de l’AACR 2025 concernant les conjugués anticorps-médicaments (CAM) OBI-992 et OBI-902, les technologies habilitantes relatives aux CAM GlycOBI® et ThiOBI®, le promédicament OBI-3424 et la science autour des antigènes Globo H (GH)
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
22/04/2025
Farmaceutica
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
12/03/2025
Farmaceutica
Annunci Economici
OBI Pharma reçoit le prix du « Candidat clinique ADC le plus prometteur à Taïwan »
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
12/03/2025
Farmaceutica
Annunci Economici
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
23/12/2024
Farmaceutica
Management/Organizzazione Aziendale
OBI Pharma entame une collaboration avec GlyTech pour étendre la portée des technologies habilitantes de GlycOBI® au Japon et faire progresser la production de glycanes
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0
23/12/2024
Farmaceutica
Management/Organizzazione Aziendale
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
Fonte
OBI Pharma Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0